Valemetostat

Valemetostat
Clinical data
Trade namesEzharmia
Other namesValemetostat tosilate (JAN); DS-3201; DS-3201b
Identifiers
  • (2R)-7-Chloro-2-[4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
FormulaC26H34ClN3O4
Molar mass488.03 g·mol−1

Valemetostat (trade name Ezharmia) is a drug used for the treatment of adult T-cell leukemia/lymphoma (ATL).

Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2), which are implicated in the etiology of some forms of cancer including non-Hodgkin lymphomas.[1][2]

In Japan, valemetostat was approved in September 2022 for patients with relapsed or refractory adult T-cell leukemia/lymphoma.[3][4]

References

  1. ^ Ishitsuka K, Izutsu K, Maruyama D, Makita S, Jacobsen ED, Horwitz S, et al. (2021). "First-In-Human Study of the Ezh1 and Ezh2 Dual Inhibitor Valemetostat Tosylate (Ds-3201B) in Patients with Relapsed or Refractory Non-Hodgkin Lymphomas". Hematological Oncology. 39 hon.14_2879. doi:10.1002/hon.14_2879. S2CID 237853028.
  2. ^ Morishima S, Ishitsuka K, Izutsu K, Kusumoto S, Makiyama J, Utsunomiya A, et al. (2019). "First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)". Blood. 134: 4025. doi:10.1182/blood-2019-125507. S2CID 209291086.
  3. ^ Dou F, Tian Z, Yang X, Li J, Wang R, Gao J (October 2022). "Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma". Drug Discoveries & Therapeutics. 16 (6) 2022.01085: 297–299. doi:10.5582/ddt.2022.01085. PMID 36310058. S2CID 253189013.
  4. ^ "Japan Green Lights Valemetostat Tosilate for Relapsed/Refractory Adult T-cell Leukemia/Lymphoma". OncLive. September 26, 2022.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.